CoChat

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis

Open access
Puengel, Tobias, De Vos, Steve, Hundertmark, Jana, Kohlhepp, Marlene, Guldiken, Nurdan, Pujuguet, Philippe, Auberval, Marielle, Marsais, Florence, Shoji, Kenji F., Saniere, Laurent, Trautwein, Christian, Luedde, Tom, Strnad, Pavel, Brys, Reginald, Clément-Lacroix, Philippe, Tacke, Frank · 2020 · Journal of Clinical Medicine
Cited by 85

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Medium-chain fatty acids (MCFAs) have been associated with anti-steatotic effects in hepatocytes. Expression of the MCFA receptor GPR84 (G protein-coupled receptor 84) is induced in immune cells under inflammatory conditions and can promote fibrogenesis. We aimed at deciphering the role of GPR84 in the pathogenesis of non-alcoholic steatohepatitis (NASH), exploring its potential as a therapeutic target. GPR84 expression is upregulated in liver from patients with non-alcoholic fatty liver disease (NAFLD), correlating with the histological degree of inflammation and fibrosis. In mouse and human, activated monocytes and neutrophils upregulate GPR84 expression. Chemotaxis of these myeloid cells by GPR84 stimulation is inhibited by two novel, small molecule GPR84 antagonists. Upon acute liver injury in mice, treatment with GPR84 antagonists significantly reduced the hepatic recruitment of neutrophils, monocytes, and monocyte-derived macrophages (MoMF). We, therefore, evaluated the therapeutic inhibition of GPR84 by these two novel antagonists in comparison to selonsertib, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, in three NASH mouse models. Pharmacological inhibition of GPR84 significantly reduced macrophage accumulation and ameliorated inflammation and fibrosis, to an extent similar to selonsertib. In conclusion, our findings support that GPR84 mediates myeloid cell infiltration in liver injury and is a promising therapeutic target in steatohepatitis and fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm9041140

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 85

Metadata

Authors
Puengel, T., De Vos, S., Hundertmark, J., Kohlhepp, M., Guldiken, N., Pujuguet, P., Auberval, M., Marsais, F., Shoji, K. F., Saniere, L., Trautwein, C., Luedde, T., Strnad, P., Brys, R., Clément-Lacroix, P., & Tacke, F.
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2020-04-16
Volume
9
Issue
4
Pages
1140
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3016341927
Cited by
85
References
13
FWCI
7.99
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis. https://app.cochat.ai/papers/10.3390/jcm9041140
The paper
Puengel, T., De Vos, S., Hundertmark, J., Kohlhepp, M., Guldiken, N., Pujuguet, P., Auberval, M., Marsais, F., Shoji, K. F., Saniere, L., Trautwein, C., Luedde, T., Strnad, P., Brys, R., Clément-Lacroix, P., & Tacke, F. (2020). The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9041140

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.